| About the author: |
L. S. Kravchenko, O. L. Appelhans, A. E. Poliakov, I. Yu. Borysiuk, Y. I. Ivanova, N. V. Neskoromna, M. V. Rosumenko |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
86 patients with metabolic syndrome and comorbid nonalcoholic fatty liver disease were carried out general clinical and laboratory-instrumental examinations. After registration of the initial data, the patients were divided into 2 groups: 41 patients with the use of rosuvastatin were added quercetin 40 mg 3 times a day for 3 months to the basic therapy (group 1). The basic therapy with rosuvastatin only was carried out in 45 patients (group 2). After the treatment on the 90th day, positive changes in lipid metabolism were registered in all the patients. The group 2 patients had a decrease in the level of low-density lipoproteins by 21.2 % (р˂0.05), an increase in high-density lipoproteins by 43.3 % (р˂0.05). The liver transaminase activity was lower by 15.0 %, concentration of pro-inflammatory interleukin-6 and cytokeratin-18 – by 10.0 % (р˃0.05). In patients of the group 1 the level of low-density lipoproteins decreased by 39.5 % (р˂0.05), the triglycerides – twice, activity of transaminase – by 30.0 % (р˂0.05). The high-density lipoproteins level increased by 72.0 % (р˂0.05). Interleukins and cytokeratin-18 concentration reliably decreased by 23.0 % (p˂0.05) (p=0.001). It was found that the comorbid course of the nonalcoholic fatty liver disease is accompanied by an increase in the oxidative stress intensity, which is determined by increased level in the blood of the end products of lipid peroxidation – malondialdehyde – on average 3.8 times (р˂0.05). The use of quercetin in the complex therapy of the nonalcoholic fatty liver disease contributes to a reliable reduction in the oxidative stress intensity, an increase in the antioxidant protection activity (superoxide dismutase), the consequence of which is a significant reduction in the hepatocytes apoptosis process (decrease in cytokeratine-18 level 1.27 times as much). |
| Tags |
metabolic syndrome,nonalcoholic fatty liver disease,hypolipidemic therapy,quercetin,inflammation |
| Bibliography |
- Bulatova IA, Shchekotova AP, Karlysheva KN. Osobennosti okislitelnogo stressa pri metabolicheskom sindrome s zhirovym porazheniiem pecheni. Sovremennyie problem nauki i obrazovaniia. 2014;2:41–47 [in Russian]
- Dynnyk NV Zastosuvannya neinvazyvnykh biomarkeriv i mistse tsytokeratynu-18 u diahnostytsi patsiientiv z nealkolnoyu zhyrovoyu khvoroboiu pechinky. Ukrayinskyy naukovo-medychnyy molodizhnyy zhurnal 2016;2(95):12–18 [in Ukrainian]
- Goryachkovskiy AM. Klinicheskaya biokhimiya v laboratornoy diagnosis. Odessa, 2005. 616 p. [in Russian]
- Lishchyna OM, Khobzei MK, Kharchenko NV. Unifikovanyy klinichnyy protokol “Nealkoholnyy steatohepatyt “Nakaz MOZ Ukrainy No. 826 vid 06.11.2014. URL: http://mtd.December_gov.ua/images/dodatki/2014.826Gepatyty/2014_826_UKRMD_NSTPT.pdf. [in Ukrainian]
- Mychka VB, Vertkin AL, Vardayev LI, Druzhilov MA, Ipatkin RV, Kalinkin AL et.al. Konsensus ekspertov po mezhdistsiplinarnomu podkhodu k vedeniyu, diagnostike i lecheniyu bolnykh s metabolicheskim sindromom. Kardiovascularnaia terapiia i profilaktika. 2013;12(6):41–81. DOI: 10/15829/1728-8800-2013-6-78-82 [in Russian]
- Chorna VV, Khlyestova SS, Humenyuk NI, Makhnyuk VM. Pokaznyky zakhvoryuvanosti i poshyrenosti ta suchasni pohliady na prophylaktyku khvorob. Visnyk Vinnytskoho natsionalnoho medychnoho universytetu 2020:24(1):158–164. DOI 10.31393/reports-vinmedical-2020-24(1)-31 [in Ukrainian]
- 2016 ESC/EAS Guidelines for the management of dyslipidemias/Developed with the special contribution of the European Association for Cardiovascular Prevention Rehabilitation (EACPR). Russ. J. Cardiol. 2017;5(145):7–77.
- Bilovol OM, Kniazkova II, Kuzminova NV, Kiriienko OM, Abramova LP, Gavrylyuk AO. Therapeutic efficacy of quercetin in patients with arterial hypertension and metabolic syndrome. World of medicine and biology. 2021;1(75):18–22. DOI: 10.26724/2079-8334-2021-1-75-18-22
- Bischoff SC, Bernal W, Dasarathy S, Merli M, Plank LD, Schuútz T et al. The European Society for Clinical Nutrition and Metabolism practical guideline: Clinical nutrition in liver disease. Modern Gastroenterology. 2021;2(118):28–40. DOI: 10.30978/MG-2021-2-28
- Finck BN. Fargeting Metabolism, Insulin Resistance and Diabetes to treat Nonalcoholic steatohepatitis. Diabetes. 2018;67(12):2485–2493. DOI: 0.2337/dbi18-0024.
- Hernandez–Baixauli J., Quesada–Vazquez S., Marine Casado R. Cardoso KG Caimari A, delBas JM et al. Detection of early disease risk factors associated with metabolic syndrome: a new era with the NMR metabolomics assessment. Nutrients. 2020;12(3):806. DOI: 10.3390/nu 12030806.
- Kang YE, Kim JM, Joung KH, Lee JH, You BR, Choi MJ et al. The Roles of Adipokines, Proinflammatory Cytokines, and Adipose Tissue Macrophages in Obesity – Associated Insulin Resistance in Modest Obesity and Early Metabolic Dysfunction. PloS One. 2016;11(4):e0154003. DOI: 10.1371/journal.pone.0154003.
- Miltonprabu S, Tomczyk M, Skalicka Wozniak K. Hepatoprotective effect of quercetin: From chemistry to medicine. Food Chem. Toxicol. 2017;108(Pt B):365–374. DOI:10.1016/j.fct2016.08.034.
- Parkhomenko A, Kozhukhov S, Lutay Y. Multicenter randomized clinical trial of the efficacy and safety of intravenous quercetin in patients with ST-elevation acute myocardial infarction. European Heart journal. 2018;39(SI):431. DOI: 10.1093/eurheartj/ehy565.2152.
- Sporea I, Popescu A, Dumitrascu D, Brise C, Nedelcu L, Trifan A, Braticevici CF. Nonalcoholic Fatty Liver Disease: Status Quo. Journal of Gastrointestinal and Liver Diseases. 2018;27(4):439–448. DOI: 10.15403/jgld.2014.1121.274.quo.
|
| Publication of the article |
«World of Medicine and Biology» №3(81), 2022 year, 076-082 pages, index UDK 616.36-003.826-06:616.12-008.331.1 |
| DOI |
10.26724/2079-8334-2022-3-81-76-82 |
